The widespread accessing of new drugs by HCPs and patients can be a very long process. Currently, venetoclax is in clinical trials for acute myeloid leukemia (AML) and hence, has not yet been approved for prescription. In this interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, encourages elderly patients with AML to participate in clinical trials, such as NCT03069352, as well as acknowledging the difficulties of this. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
Advising AML patients to participate in clinical trials
